Chidamide treatment upregulated PD-L1 expression on tumor cells in a dose-dependent manner over 48 hours, increasing tumor sensitivity to PD-1/PD-L1 antibodies (Fig. 3E). The gene discussed is PDCD1; the disease is neoplasm.